In a New England Journal of Medicine correspondence (Central Nervous System and Limb Anomalies in Case Reports of First-Trimester Statin Exposure. NEJM 350, 1579-1582, 2004) is shown an interesting evaluation of the exposure to statin during pregnancy. The cholesterol-lowering statin drugs are contraindicated in pregnancy, therefore few data exist regarding their safety in human gestation. The authors reviewed 178 cases of first-trimester statin exposure reported to the Food and Drug Administration (FDA) from 1987 through 2001 for patterns suggesting possible drug-related effects on embryogenesis. After the exclusion of cases involving first-trimester elective or spontaneous abortions (46 and 42 cases, respectively), pregnancy loss due to maternal illness (15), fetal genetic disorders (3), transient neonatal disorders (5), or loss to follow-up (15), 52 cases were considered evaluable.

Definite central nervous system and limb anomalies were found.


BM&L- April 2004